chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1130: Patient c/o dizziness approximately 15 minutes post vaccine. Patient stood up dizziness increased.  PMHx: Epstien Barr, Bradycardia, Tachycardia Stage II Renal Disease Patient A & O x4, skin pink, warm and dry, PERRLA ~3mm Speech clear and appropriate. EMS and Physician on duty at bedside assessing patient.   VS:1127:156/106-b/p, 60-hr, SaO2 96% on RA,  1141 VS: 154/104, Repeat 146/98 58-HR, SaO2 98% on RA EKG, VS as above. Patient advised to be evaluated in ED. Patient refused ambulance transport. Symptoms subsided, minimal at the time of departure ~1210. Patient taken to care via wheelchair. Daughter to transport to ED by Patient's own vehicle.
Migraine with aura 28 hours post vaccination, took 2 Excederin, migraine resolved with sleep. Additional aura (visual disturbance) 12/26 (3 days 20 hrs post vaccination). Took 2 Extra Strength Tylenol and symptoms resolved without additional migraine. Prior to this, my last migraine was about a month ago. Typically I only get migraines every 2-3 mo, so this was atypical for me.
From injection c/o hurt 4-5days. Today 10/8/14 hard to lift arm-giving her much pain. Referred to one of our offices for evaluation and treatment. Patient has also contacted work partners.
systemic side effects (fatigue); systemic side effects (myalgia); This case was reported by a pharmacist via sales rep and described the occurrence of fatigue in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fatigue and myalgia. On an unknown date, the outcome of the fatigue and myalgia were recovered/resolved.   It was unknown if the reporter considered the fatigue and myalgia to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced systemic side effects fatigue, myalgia for a day. The reporter did not consent to follow up.
Facial weakness & numbness x 3days. Difficulty speaking and controlling mouth and eyes. C/o headache and left earache.
Car sick driving home and lightheaded, dizzy that continued for several weeks including date of this report.
It seemed like I had throat tightness but it wasn't not severe and the 2nd day my right arm was itchy and red, swollen for a couple of days, It also increased Tachycardia for 5 days.
slight left armpit swelling and pain; slight left armpit swelling and pain; chills and slight aches 12 hours after 2nd injection; chills and slight aches 12 hours after 2nd injection; This is a spontaneous report from a contactable nurse (patient). A 29-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231, expiry date not reported), via an unspecified route of administration in the left arm on 24Jan2021 at single dose for COVID-19 immunization. Medical history was not reported. Concomitant medications were none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was vaccinated at a hospital. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient has not been tested for COVID-19. The patient had no allergies to medications, food, or other products. The patient previously received first dose of bnt162b2 (lot number: EK5730, expiry date not reported), intramuscular in the left arm on 04Jan2021 07:45 AM at single dose for COVID-19 immunization. On 24Jan2021 22:30, the patient experienced chills and slight aches 12 hours after 2nd injection. On 25Jan2021, 24 hours after 2nd injection, the patient experienced slight left armpit swelling and pain. No treatment was received for the adverse events. Clinical outcome of the events was not recovered.
PATIENT STARTED TO HAVE SEIZURE WHILE SHE WAS IN HER WHEELCHAIR ABOUT 10 MINUTES AFTER HER VACCINATION. PATIENT'S DAUGHTER AND I WERE WITH HER WHILE SHE WAS HAVING SEIZURE. SHE WAS AWARE WHAT WAS GOING ON BUT HER BODY WAS SPASMING. SHE DID NOT HIT HER HEAD AS SHE WAS IN HER CHAIR AND DAUGHTER ASKED US NOT TO CALL AMBULENCE (OFFERED TO CALL RIGHT AWAY) AS HER SEIZURES USUALLY PASS AFTER A FEW MINUTES. AFTER A FEW MINUTES (PATIENT WAS SITTING WHOLE TIME), SEIZURE PASSED AND HER BODY WAS NOT SPASMING, PATIENT STAYED FOR ADDITIONAL 20 MINUTES TO BE MONITORED IN CASE ANYTHING HAPPENED.  NO TREATMENT WAS GIVEN EXCEPT GIVING PATIENT WATER (PATIENT HAS HISTORY OF LYMPHOMA, SEIZURES (ON MEDICATION FOR IT PER DAUGHTER)). AFTER 30 MINUTES, PATIENT RECOVERED AND WAS BACK  TO NON-SEIZURE STATE. DAUGHTER STATED IT WAS FINE TO LEAVE AND NO ADDITIONAL HELP WAS NEEDED AND PATIENT WITH DAUGHTER LEFT.
p/vax pt exp multiple 25-50 varicella lesions on face/legs/fingers
came to clinic for a sports physical & recvd TD; later the same day devel tenderness, edema @ inject site & swollen glands in axilla; also c/o malaise, feels like the flu; still feeling bad on 18NOV94 arm still swollen;
Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 07/28 pt wife called cc: chest pain, cough, dyspnea, weakness. SOB, headache 08/04 COVID swab, result: detected 08/04 hospitalized dx. PNA 08/04 CXR impression: Bilateral pneumonia. 08/05 CXR impression: Persistent mixed interstitial and patchy airspace opacities in the mid and lower lungs bilaterally not significantly changed. Findings with patient's known history of COVID pneumonia. 08/09 Fungitell result <31 08/09 CXR impression: Stable chest radiograph since 4 days ago as above. 08/10 Tacrolimus result: 7.4 08/10 ESR 12 8/10 Fibrinogen/ DDIMER results: 261/ 1.11 8/10 CXR impression: Similar groundglass and interstitial opacities in the lungs, consistent with atypical pneumonia. 08/11 ESR 8 08/11 Fibrinogen/ DDIMER result: 230/ 0.99 08/11 CXR impression: Similar appearance of bilateral lung opacities. 08/12 ESR result: 6 08/12 Fibrinogen/ DDIMER result: 203/ 1.11 08/13 ESR result: 7 08/13 Fibrinogen/ DDIMER result: 216/ 1.16 08/14 Fungitel result: <31 08/14 ESR result: 12 08/14 Fibrinogen/ DDIMER result: 207/ 1.37 08/14 Procalcitonin result: 0.07 08/14 CXR impression: Underinflated lungs. Interval increase in bilateral opacities accentuated by differences in technique. 08/15 ESR result: 13 08/15 Fibrinogen/ DDIMER result: 212/ 1.08 08/15 CT Chest impressions: Multifocal bilateral groundglass opacities throughout both lungs with more confluent involvement at the posterior lung bases. This may reflect a nonspecific infectious/inflammatory process, including the possibility of viral pneumonia in the setting of known COVID positivity. Interlobular septal thickening is also present component of pulmonary edema may also be considered. Clinical correlation and attention on short-term follow-up is recommended to assess for clearance. 2. Oval nodular opacity at the posterior left upper lobe which may reflect nonspecific infection/inflammation with neoplasia not excluded. Attention on short-term follow-up is recommended. 3. Ectasia of the ascending thoracic measurement of 4.1 cm in diameter. 08/16 ESR result: 5 0816 Fibrinogen/ DDIMER result: 226/ 0.87 08/17 Fibrinogen/ DDIMER result: 230/ 0.98 08/17 ESR 11 08/17 Tacrolimus result: 2.1 08/18 ALT/AST result: 27/38 08/18 ESR result: 11 08/18 Fibrinogen/ DDIMER result: 226/ 1.22 8/18 ABG result: i-pH 7.41, i-PCO2 34.9, i-Po2 65, i-HCO3 22.1 8/18 C-Reactive result: 0.114 8/19 ESR result: 10 8/19 Fibrinogen/ DDIMER result: 216/ 1.87 8/20 BNP result: 136.3 8/20 ESR result: 14 8/20 Fibrinogen/ DDIMER result: 258/ 1.53 8/21 CXR Impression: Essentially stable chest radiography since 6 days ago with imaging findings most in keeping with ongoing COVID pneumonitis 8/21 Fibrinogen/ DDIMER result: 271/ 1.66 8/21 ALT/AST Result: 35/ 44 8/21 ferritin result: 2211 8/21 C-Reactive Protein result: 0.272 8/21 ESR 12 8/21 CXR Impression: Diffuse bilateral airspace opacities, mildly worsened. Low lung volumes. 8/22 Fibrinogen/ DDIMER Result: 296/ 2.08 8/22 ALT/AST result: 41/43 8/22 C-Reactive Protein result: 0.240 8/22 ESR 30 8/24 pt decease
HALF-DOLLAR SIZE BRUISE ON LEFT UPPER THIGH; MILD HEADACHE OFF AND ON LASTING  SECONDS; SORENESS IN THE LEFT ARM FROM INJECTION; This spontaneous report received from a patient concerned a 58 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: 207A21A, and expiry: UNKNOWN) dose was not reported, administered on 10-MAY-2021 for prophylactic vaccination. Concomitant medications included acetylsalicylic acid, and dulaglutide. On 10-MAY-2021, the subject experienced soreness in the left arm from injection. On 11-MAY-2021, the subject experienced half-dollar size bruise on left upper thigh. On 11-MAY-2021, the subject experienced mild headache off and on lasting seconds. The action taken with covid-19 vaccine  was not applicable. The patient had not recovered from soreness in the left arm from injection, and half-dollar size bruise on left upper thigh, and the outcome of mild headache off and on lasting seconds was not reported. This report was non-serious.
Vacine one: changed my menstrual cycle, menstruated cycle came a week later than expected  Vacine 2: change menstrual cycle, period came a week sooner and lasted for 2 weeks.  ( normally my me atrial cycle only lasted 3-4 days, but after Vacine two it lasted for 14 days)   My brother:  after having the first Pfizer Vacine, he has mild headchace, ringing in ear, broke out in hives and skin looks bruised.  So he stopped and dudnot receive vacine second shot.
Arm swelling at injection site leading to welt and Severe itchiness at injection site as well as chest and legs. Patient to follow up with primary care
2 month old male with inconsolable crying for 2 1/2 hours duration (2-3hrs) post vaccination.
pt recv vax & became pregnant;LMP 31JUL95;estimated date of delivery 7MAY96;@ 33wk pt devel pregnancy-induced HTN, & @ 34wk gestational diabetes;tx w/meds;26APR96 pt exp placental abruption requiring Cesarean section;
Hives; Itching; This is a spontaneous report received from a contactable consumer (Patient). A 75-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EL9265), Solution for injection, via an unspecified route of administration on 26Jan2021 11:10 (at the age of 75-years-old) as single dose for covid-19 immunisation. Medical History (including any illness at time of vaccination) was reported as none. There were no concomitant medications. Patient previously received flu shot in Sep2020. No additional vaccines administered on same date of the Pfizer suspect. Patient did not receive any vaccine within four weeks of Pfizer vaccine. On 19Feb2021, the patient experienced hives and itching. Patient received the first dose of the Covid-19 vaccine 2 Jan2021. She was scheduled to get the second dose last Tuesday 16Feb2021. It was canceled due to bad weather. She was rescheduled for today. She was having a reaction to something. She cant imagine it would take that long. She had hives and itching. It started on her right arm and is not on her left arm. The itching was not as bad. It was controlled with Benadryl. No relevant test was performed. Patient did not visit emergency Room or physician office. Therapeutic measures were taken as a result of itching. The outcome of event hives was not recovered and itching was recovering.    Follow-up attempts are completed. No further information is expected.
1 of Shingrix on September 7, 2018 / dose 2 on April 18, 2019; shingles; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included non-hodgkin's lymphoma. Previously administered products included Shingrix (received 1st dose on 7th September 2018). Concomitant products included rituximab.   On 18th April 2019, the patient received the 2nd dose of Shingrix. In April 2019, less than 2 weeks after receiving Shingrix, the patient experienced shingles. On 18th April 2019, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the shingles was not recovered/not resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The patient received dose 1 of Shingrix in 7th September 2018, and 2nd dose in 18th April 2019, which led to drug dose administration interval too long. The patient developed shingles in late April 2019, and till the time of reporting patient was not recovered for shingles The reporter consented to follow up.
Had 3 episodes of vomiting, then followed by limpness and eyes rolling back, lasting about 30 seconds.  Did have fever 102 F in ER.  Next day had another limp, eyes rolling back episode not associated with vomiting or fever.
Beginning 4 hours post injection some swelling was noticed at the injection site. Upon waking (roughly 8 hours later) the swelling at the injection site had intensified and red spots appeared from shoulder to thumb on the injected arm.
6/25 Evening of day vaccine administered c/o stomach ache. Cont. with stomach ache but decreased in severity. 6/26 - no diarrhea/vomiting/fever. Blisters started to form bottom lip. 6/27 Blisters increased on bottom lip. Seen by Dr. Continues to have blisters. No fever, no other sx.
Pain on left side of back under rib cage, intermittent left arm numbness and slight chest tightness. Narrative:
Patient states that she developed a nickle sized rash that was warm, red and painful on 2/11/21 after receiving the Moderna COVID vaccine on 2/4/21.  She presented to her provider who thought she may have a cellulitis.  She was prescribed an antibiotic, but the area of redness has not improved since starting the antibiotic.  No systemic symptoms such as fever.
Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On or about 27-JUN-2008,  the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles. On or about 16-NOV-2016, the patient was treated at a medical facility for a blistering vesicular outbreak, which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
1st flu vaccine for this pt. Was given in AM. Pt developed dizziness, lightheadedness, and increase of BP. When seen in my office in mid afternoon BP was still 160/98. Pt was observed and monitored in office until BP returned to normal.
every time he gets some what sick after it; Initial information received on 17-Oct-2021 regarding an unsolicited valid Social Media non-serious case from a consumer/non-health care professional via Digital Media.  This case involves a patient (unknown age and gender) who was sick (illness) after receiving INFLUENZA VACCINE.  It was unknown if the patient had any medical history, concomitant disease or risk factor.  Medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiration date were not reported) via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick (illness, non-serious) (unknown latency) following the administration of vaccine.  It was reported "Flu starts every year with the flu shots. What a coincidence. I have a fried who gets and every time he gets some what sick after it and spreads it around so we all get a share."  It was unknown if the patient experienced any additional symptoms/events.  It was unknown if there were laboratory data/results available.  It was not reported if the patient received a corrective treatment.  At time of reporting, the outcome was unknown for the reported event.  There will be no information available on the batch number for this case.
Pt had itchy eyes and tingly lips. Vitals stable. Pt given two tablets of Benadryl and reported relief in symptoms.
Patient became confused a few minutes after her vaccination and the proceeded to pass out.  Her heart rate was in the 50s for a few minutes, but her blood pressure was fine when laying down.  She recovered within 30 minutes.
Initial report was received from the scientific literature on 22 February 2013. Verbatim from the report: "Background: The delivery of the DPT vaccine has been plagued by concerns about a causal link to epilepsy and encephalopathy. The NVICP is a national effort within the Department of Health and Human Services to compensate children who develop neurologic problems within 72 hours of immunization. Objective: To describe clinical characteristics of children alleging seizure disorder as an injury due to vaccination. Methods: Retrospective record review of vaccine-alleged seizure disorder cases in children aged <2 years filing claim during 1995-2004. Results: NVICP retrieved 242 cases alleging seizure disorder as vaccine injury. Of 96 cases reviewed thus far, 71 were filed in 1995-6, 10 in 1997-2002. Half were male. Vaccines implicated (sometimes multiple) were DPT 75, MMR17, Hib and DT 2 each, DTaP and OPV one each. Less than half (42%) had a seizure within 72 hours of vaccination. There was a history of seizure before the alleged vaccine injury in 18%, abnormal neurological examination before the alleged vaccine injury in 13%. A definite diagnosis of pre-existing abnormality (tuberous sclerosis, epilepsy, congenital malformations, developmental delay) was given in 11%. Chronic myoclonic epilepsy developed in a quarter of the children. Conclusion: A significant number of children with alleged vaccine induced seizure disorders had pre-existing neurological or neurodevelopmental abnormalities. Among those developing chronic epilepsy, many had clinical features suggesting genetically determined epilepsy. Future studies of these children, including genotyping, may allow more specific therapy and prognostication and may have implications for public confidence in vaccination." Documents held by sender: none.
I had either joint or muscle pain (on her back, just one side); I had either joint or muscle pain (on her back, just one side); This is a spontaneous report received from a contactable consumer. A 73-year-old female consumer (Patient) reported for herself that she received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number, NDC Number, UPC Number, Expiry Date: Unknown), via an unspecified route of administration on 02Feb2021 as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient got the shot and she had either joint or muscle pain (on her back, just one side). She wanted to know if she could receive dose 2. She had received the Pfizer-BioNTech COVID-19 vaccine approximately 8 days ago, her first dose. She guessed that it was the vaccine, she did not have it (prior to vaccination). She experienced similar symptoms (joint pain and/or muscle pain) was not described as a contraindication to receive the 2nd dose. She was suggested to contact her Doctor, to mention the symptoms experienced and confirm if the 2nd dose should be administered. Already called her doctor, and she was waiting for a response. Consumer was not willing to proceed with the questions, hence limited information was available on the call. The outcome of events was unknown.  Follow-up attempts are completed. No further information is expected.
Pt vaccinated with Hepatitis B vaccine severe progressive encephalomyelitis with chronic demyelinizing disease.
Shot was administered at 28 weeks +6 days pregnant and preterm labor (PPROM) started at 29 weeks +1 day pregnant.  I was hospitalized and delivered at 31 weeks + 5 days. Baby was 3 lbs 14 oz.
pain; redness; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On 28th June 2019, the patient received the 2nd dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced injection site pain and injection site erythema. On an unknown date, the outcome of the injection site pain and injection site erythema were unknown.   It was unknown if the reporter considered the injection site pain and injection site erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The 1st dose was administered on 2nd May 2019, concomitantly. The caller reported that the patient received Shingrix and had been experiencing pain and redness at the injection site.  Did not consent to follow up. Related to Patient. The reporters declined to provide any additional information. This is 1 of the 2 cases reported by the same reporter.
Covid positive/symptoms: cough, congestion and "more" body aches, lost taste and fever for a day; Covid positive/symptoms: cough, congestion and "more" body aches, lost taste and fever for a day; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 51 year-old male patient received bnt162b2 (COMIRNATY), administration date 11Apr2021 (Lot number: EP7533) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "diabetes" (unspecified if ongoing); "skipping heart beats" (unspecified if ongoing), notes: ("fibulations"). Family history included: "GI cancer" (unspecified if ongoing), notes: paternal; "high blood pressure" (unspecified if ongoing), notes: paternal; "Cancer" (unspecified if ongoing), notes: father died of Cancer and mother was living and currently has no medical conditions. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 21Dec2021, outcome "unknown", COVID-19 (medically significant) with onset 21Dec2021, outcome "recovered" (Dec2021) and all described as "Covid positive/symptoms: cough, congestion and "more" body aches, lost taste and fever for a day". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (23Dec2021) positive. Therapeutic measures were taken as a result of covid-19. Clinical course: The patient was diagnosed with Covid positive on 23Dec2021, but the symptoms started around 21Dec2021, soon after his son. The symptoms included cough, congestion and "more" body aches, lost taste, and fever for a day; the patient took Tylenol. The patient acquired Covid through his son, who lives together with daughter and wife. The symptoms resolved near 29Dec2021 or on 30Dec2021. The patient did not receive the booster and the last dose of Comirnaty was administered on 11Apr2021. No follow-up attempts are possible. No further information is expected.
Narrative: Patient was found to have acute hepatitis by labs 13 days and by biopsy 17 days after vaccination. LTFs gradually improved. Labs for syphilis , acute viral hepatitis did not shed any light . Re-challenged with trim-sula did not cause LFTs elevation. Moderna vaccine 2nd dose was not given because of severity of initial reaction.